Tricyclic derivative and application thereof
By developing tricyclic derivatives as inhibitors of 5-HT and NA reuptake and agonists or antagonists of 5-HT1A receptors, the problems of slow onset and numerous side effects of existing tricyclic antidepressants have been solved, achieving faster and stronger antidepressant effects.
Patent Information
- Application Number
- CN202410332103.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-22
- Publication Date
- 2024-11-26
AI Technical Summary
Existing tricyclic antidepressants have problems such as long onset time, many side effects and low response rate when treating depression, and the effect of using 5-HT1A receptor partial agonists alone is weak.
To develop a tricyclic derivative as an inhibitor of 5-HT and NA reuptake and a 5-HT1A receptor agonist or antagonist for the treatment of depression, by inhibiting 5-HT reuptake and agonizing or antagonizing 5-HT1A receptors to promote 5-HT release and enhance antidepressant effects.
This tricyclic derivative has a faster onset of action, a wider range of indications, and fewer neurotoxic side effects, providing a stronger antidepressant effect.
Smart Images

Figure CN119019331A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicine, and specifically relates to a tricyclic derivative and its application or its pharmaceutically acceptable salt, stereoisomer, tautomer and composition containing the compound, as well as the tricyclic derivative or its pharmaceutical composition as a 5-HT and NA reuptake inhibitor and / or 5-HT 1A The use of receptor agonists or antagonists in the treatment of depression. Background Art
[0003] Tricyclic antidepressants (TCAs) are the most classic antidepressants, and the main drugs include amitriptyline, amoxapine, clomipramine, dosulpine, doxepin and imipramine, etc. The mechanism of action of this type of drug is to inhibit the reuptake of NE and 5-HT released in the synaptic cleft by neurons, thereby increasing the content of monoamine transmitters in the synaptic cleft and producing an antidepressant effect.
[0004]
[0005] Structure of classic tricyclic antidepressants
[0006] However, while these drugs exert their antidepressant effects, they also block other neurotransmitter receptors, resulting in many adverse reactions, such as constipation, blurred vision, urinary retention, tachycardia, postural hypotension, weight gain, increased appetite, etc. In addition, these drugs generally have disadvantages such as low response rate and long onset time.
[0007] Classic antidepressants can increase 5-HT levels in the synaptic cleft within a few hours, but at the same time activate 5-HT in the raphe nucleus. 1A The autoreceptors produce negative feedback inhibition, causing a decrease in 5-HT neuron discharge, reducing 5-HT synthesis and release. After 2 to 4 weeks of administration, 5-HT 1A Autoreceptor desensitization, reduced expression, weakened negative feedback inhibition, and restoration of normal discharge of 5-HT neurons may be an important reason for the delayed onset of antidepressant drugs.
[0008] Clinically, it has been found that the use of 5-HT alone 1A Partial agonists of 5-HT receptors (such as buspirone and ixabepilone) have only a weak antidepressant effect. 1A The combined use of partial receptor agonists and SSRIs can significantly shorten the onset time and enhance the antidepressant effect. On January 21, 2011, the US FDA approved vilazodone for the treatment of depression. Mechanism studies have shown that vilazodone inhibits 5-HT reuptake and increases 5-HT content in the synaptic cleft; it stimulates presynaptic 5-HT 1Aautoreceptors, promoting their desensitization and 5-HT release; at the same time, directly stimulating postsynaptic 5-HT 1A Receptors, enhancing 5-HT neurotransmission, with a potent and rapid antidepressant effect.
[0009]
[0010] Therefore, the development of antidepressants with faster onset of action, more stable long-term efficacy and fewer side effects remains an urgent clinical need. Summary of the invention
[0011] The following is a summary of some aspects of the present invention, but is not intended to limit the present invention. When there is a discrepancy between the disclosure of this specification and the referenced document, the disclosure of this specification shall prevail.
[0012] The present invention provides a tricyclic derivative and its application or its pharmaceutically acceptable salt, stereoisomer, tautomer and composition containing the compound, and the tricyclic derivative or its pharmaceutical composition as a 5-HT and NA reuptake inhibitor and 5-HT 1A The use of receptor agonists or antagonists in the treatment of depression.
[0013] The object of the present invention is to provide a compound as represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof.
[0014]
[0015] in:
[0016] R1 and R2 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio;
[0017] R3 is oxygen or sulfur;
[0018] R4 is hydrogen, deuterium, halogen, hydroxyl, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio;
[0019] Q is CR5R6 or NR7;
[0020] R5 and R6 are each independently hydrogen, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio; or R5 or R6 and R4 and the carbon atom to which they are connected together form C 6-14 Aryl; or R5 is In this case, R6 is hydrogen, wherein Ar is a 5-8 membered heterocyclic group, R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a substituted aryl group optionally replaced by one or more R 10 Substituted C 6-14 Aryl;
[0021] R7 is Where Ar is a 5-8 membered heterocyclic group, C 6-14 R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a radical optionally substituted by one or more R 10 Substituted C 6-14 Aryl, or R8 and R9 together with the carbon atom to which they are attached form an aryl group optionally with one or more R 10 substituted 5-8 membered heterocyclic group;
[0022] R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio;
[0023] x is an integer from 0 to 4;
[0024] y is an integer from 0 to 4;
[0025] m is an integer from 2 to 8.
[0026] Furthermore, the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, tautomer, satisfies one or more of the following conditions:
[0027] (1) R1 and R2 are each independently hydrogen, deuterium, halogen, or hydroxyl;
[0028] (2) R3 is oxygen or sulfur;
[0029] (3) R4 is hydrogen, deuterium, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl;
[0030] (4) Q is CR5R6 or NR7;
[0031] R5 and R6 are each independently hydrogen, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; or R5 or R6 and R4 and the carbon atom to which they are attached together form a C 6-14 Aryl; or R5 is In this case, R6 is hydrogen, wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, and R8 and R9 together with the carbon atom to which they are attached form a group optionally replaced by one or more R 10 Substituted C 6-14 Aryl;
[0032] R7 is wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, C 6-14 R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a 5-14 membered heteroaryl group optionally substituted by one or more R 10 Substituted C 6-14 Aryl, or R8 and R9 together with the carbon atom to which they are attached form an aryl group optionally with one or more R 10 A substituted 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S; R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio;
[0033] x is an integer from 0 to 4;
[0034] y is an integer from 0 to 4;
[0035] m is an integer of 2-4.
[0036] Furthermore, the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, tautomer, the general formula (I) is further represented by the general formula (II), the general formula (III) or the general formula (IV):
[0037]
[0038] Wherein, R1 is hydrogen, deuterium, halogen, or hydroxyl;
[0039] R3 is oxygen or sulfur;
[0040] R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a 5-8 membered heterocyclic group containing a S heteroatom;
[0041] m is an integer of 2-4.
[0042] Furthermore, the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, tautomer, the general formula (I) is further represented by the general formula (V) or the general formula (VI):
[0043]
[0044] Wherein, R1 is hydrogen, deuterium, halogen, or hydroxyl;
[0045] R3 is oxygen or sulfur;
[0046] R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio;
[0047] m is an integer of 2-4.
[0048] Furthermore, the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, tautomer is selected from the following compounds:
[0049]
[0050]
[0051]
[0052] In a further preferred embodiment of the present invention, the pharmaceutically acceptable salt is selected from hydrochloride, hydrobromide, sulfate, phosphate, succinate, malonate, acetate, oxalate, benzoate, citrate, tartrate, nicotinate, lactate, furoate, maleate, fumarate, methanesulfonate, ethanesulfonate, benzenesulfonate or p-toluenesulfonate.
[0053] The present invention further provides a method for preparing the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, or tautomer, which can be synthesized using commercially available raw materials by known methods, comprising the following steps:
[0054] Step 1:
[0055]
[0056] Step 2:
[0057]
[0058] Wherein, R1, R3, and R4 are as defined in any one of the preceding claims;
[0059] Q is CR5R6 or NR7;
[0060] R5 and R6 are as defined in any one of the preceding claims;
[0061] Or R5 is In this case, R6 is hydrogen, wherein Ar, R8, and R9 are as defined in any one of the preceding claims;
[0062] R7 is Among them, Ar, R8, R9, R 10 As defined in any of the preceding claims;
[0063] R 11 is a halogen;
[0064] R 12 is halogen, hydroxyl;
[0065] m is an integer of 2-8, and preferably m is an integer of 2-4.
[0066] Furthermore, a method for preparing the compound represented by the general formula (I) or its pharmaceutically acceptable salt, stereoisomer, or tautomer is provided. The method can be synthesized using commercially available raw materials by known methods, and comprises the following steps:
[0067] Step 1:
[0068]
[0069] Step 2:
[0070]
[0071] Wherein, R1 is hydrogen or halogen;
[0072] R3 is oxygen or sulfur;
[0073] R4 is hydrogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl;
[0074] Q is CR5R6 or NR7;
[0075] R5 and R6 are each independently hydrogen, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; or R5 or R6 and R4 and the carbon atom to which they are attached together form a C 6-14 Aryl; or R5 is In this case, R6 is hydrogen, wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, and R8 and R9 together with the carbon atom to which they are attached form a group optionally replaced by one or more R 10 Substituted C 6-14 Aryl;
[0076] R7 is wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, C 6-14 R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a 5-14 membered heteroaryl group optionally substituted by one or more R 10 Substituted C 6-14 Aryl, or R8 and R9 together with the carbon atom to which they are attached form an aryl group optionally with one or more R 10 A substituted 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S; R 10 is hydrogen, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio;
[0077] R 11 is a halogen;
[0078] R 12 is halogen, hydroxyl;
[0079] m is an integer of 2-4.
[0080] The present invention further relates to a pharmaceutical composition comprising a therapeutically effective dose of any of the compounds shown or a pharmaceutically acceptable salt, stereoisomer, tautomer thereof and one or more pharmaceutically acceptable carriers or excipients.
[0081] In some embodiments of the present invention, the pharmaceutical composition can be prepared in a conventional manner using one or more pharmaceutically acceptable carriers. The carrier refers to a conventional carrier in the pharmaceutical field, for example: a diluent such as water, etc.; a binder such as a cellulose derivative, gelatin, polyvinyl pyrrolidone, etc.; a filler such as starch, etc.; a disintegrant such as calcium carbonate, sodium bicarbonate; a lubricant such as calcium stearate or magnesium stearate, etc. In addition, other adjuvants such as sweeteners, aromatics or colorants can also be added to the composition.
[0082] In some embodiments of the present invention, the pharmaceutical composition can be administered in any of the following ways: oral administration, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal or intracranial injection or infusion, or administration via an explanted reservoir, wherein oral administration is preferred.
[0083] When administered orally, the compounds of the present application can be prepared into any orally acceptable preparation form, including but not limited to tablets, capsules, aqueous solutions or aqueous suspensions, etc.
[0084] The present invention further relates to the use of any of the compounds shown or their pharmaceutically acceptable salts, stereoisomers, tautomers, or pharmaceutical compositions thereof in the preparation of 5-hydroxytryptamine 5-HT and norepinephrine NA reuptake inhibitors and / or 5-HT1A receptor agonists.
[0085] The present invention also relates to the use of any of the compounds or their pharmaceutically acceptable salts, stereoisomers, tautomers, or pharmaceutical compositions thereof in the preparation of drugs for preventing and / or treating neuropsychiatric diseases.
[0086] In a further preferred embodiment of the present invention, the neuropsychiatric disease is selected from one or more of schizophrenia, depression, pain, sleep disorder or Alzheimer's disease, preferably depression.
[0087] The present invention also relates to a method for preventing and / or treating neuropsychiatric diseases, which comprises administering to the mammal a therapeutically effective dose of any of the compounds shown, its stereoisomers or pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates or derivatives thereof, or a pharmaceutical composition thereof.
[0088] General Terms and Definitions
[0089] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. In the event of a conflict, the definitions provided herein shall prevail. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient. All patents, published patent applications and publications cited herein are incorporated herein by reference.
[0090] The term "optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0091] The term "optionally substituted" can be used interchangeably with the term "substituted or unsubstituted", that is, the structure or group is unsubstituted or substituted by one or more substituents described in the present invention, wherein the substitution occurs at any reasonable position allowed by the valence of the given structure or group. If the substitution occurs on a structure or group that does not allow substitution, the substituent does not exist.
[0092] Unless otherwise indicated, as used herein, the point of attachment of a substituent may be from any convenient position of the substituent. When a bond to a substituent is shown as passing through a bond connecting two atoms in a ring, then such a substituent may be bonded to any ring-forming atom in the substitutable ring.
[0093] In general, the term "substituted" means that one or more hydrogen atoms in a given structure or group are replaced by a specific substituent. Unless otherwise indicated, a substituent can be substituted at each reasonable position of the group. When more than one position in the given structural formula can be substituted by one or more specific substituents selected, the substituent can be substituted at each reasonable position in the structural formula in the same or different manner.
[0094] In addition, it should be noted that, unless explicitly stated otherwise, the description method used in the present invention "respectively and independently are" or "each independently" should be understood in a broad sense, which can mean that in different groups, the specific options expressed by the same symbols do not affect each other, or that in the same group, the specific options expressed by the same symbols do not affect each other.
[0095] When the lower and upper limits of a numerical range are disclosed, any numerical value and any included range falling within the range are specifically disclosed. In particular, each range of values disclosed herein should be understood to represent each numerical value and range encompassed within a wider range. When any variable (e.g., Ra), and variables with markers (e.g., R1, R2, R3, R4, R5, R6, R7, etc.) appear more than once in the composition or structure of a compound, their definitions in each case are independent at each occurrence. For example, if a group is substituted with 0, 1, 2, or 3 Ra substituents, the group may optionally be substituted with up to three Ra substituents, and the options for each Ra substituent in each case are independent of one another, i.e., each Ra substituent may be the same or different.
[0096] In various parts of this specification, the substituents of the disclosed compounds of the present invention are disclosed according to group types or ranges. It is particularly pointed out that the present invention includes each independent subcombination of the individual members of these group types and ranges. For example, the expression mn used herein refers to the range of m to n and the subranges composed of the individual point values therein and the individual point values.
[0097] The term "alkyl" refers to a saturated straight-chain or branched aliphatic hydrocarbon group having 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms. 1-20 The alkyl group is preferably an alkyl group having 1 to 12 carbon atoms (i.e., C 1-12 alkyl), more preferably an alkyl group having 1 to 8 carbon atoms (i.e., C 1-8 Alkyl), further preferably an alkyl group having 1 to 6 carbon atoms (i.e., C 1-6 Alkyl), most preferably an alkyl group having 1 to 3 carbon atoms (i.e., C 1-3Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2 ,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched chain isomers thereof. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0098] The term "alkylene" refers to a divalent alkyl group, wherein alkyl is as defined above, having from 1 to 20 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) carbon atoms (i.e., C 1-20 The alkylene group is preferably an alkylene group having 1 to 12 carbon atoms (i.e., C 1-12 alkylene), more preferably an alkylene group having 1 to 8 carbon atoms (i.e., C 1-8 Alkylene), further preferably an alkylene group having 1 to 6 carbon atoms (i.e., C 1-6 Alkylene), most preferably an alkylene group having 1 to 3 carbon atoms (i.e., C 1-3Alkylene). Non-limiting examples include: -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH(CH2CH3)-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, etc. Alkylene can be substituted or unsubstituted, and when substituted, the substituent can be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups, which are independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0099] The term "alkenyl" refers to an alkyl group containing at least one carbon-carbon double bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkenyl group is preferably an alkenyl group having 2 to 6 carbon atoms (i.e., C 2-6 The term "alkenyl" refers to a group consisting of a vinyl group, a 1-propenyl group, a 2-propenyl group, a 1-, 2- or 3-butenyl group, and a 3-butylene group. The alkenyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0100] The term "alkynyl" refers to an alkyl group containing at least one carbon-carbon triple bond in the molecule, wherein alkyl is as defined above and has 2 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12) carbon atoms (i.e., C 2-12 The alkynyl group is preferably an alkynyl group having 2 to 6 carbon atoms (i.e., C 2-6 Alkynyl). Non-limiting examples include: ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Alkynyl can be substituted or unsubstituted, and when substituted, the substituent can be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups, which are independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0101] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic hydrocarbon substituent (i.e., monocyclic cycloalkyl) or polycyclic hydrocarbon substituent (i.e., polycyclic cycloalkyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) carbon atoms, i.e., C 3-20 The cycloalkyl group is preferably a cycloalkyl group having 3 to 12 carbon atoms (i.e., C 3-12 cycloalkyl), more preferably a cycloalkyl having 3 to 8 carbon atoms (i.e., C 3-8 cycloalkyl), further preferably a cycloalkyl having 3 to 6 carbon atoms (i.e., C 3-6 cycloalkyl), most preferably a cycloalkyl having 3 to 5 carbon atoms (i.e., C 3-5 cycloalkyl), or a cycloalkyl having 5 to 6 carbon atoms (i.e., C 3-5 The non-limiting examples of the monocyclic cycloalkyl include: cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl and cyclooctyl. The non-limiting examples of the polycyclic cycloalkyl include: spirocycloalkyl, fused cycloalkyl and bridged cycloalkyl.
[0102] The cycloalkyl may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl. The cycloalkyl may be optionally substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, sulfhydryl, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0103] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic heterocyclic hydrocarbon substituent (i.e., a monocyclic heterocyclyl) or a polycyclic heterocyclic hydrocarbon substituent (i.e., a polycyclic heterocyclyl) having 3 to 20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20) ring atoms (i.e., a 3-20 membered heterocyclyl), wherein one or more (e.g., 1, 2, 3 or 4) ring atoms are selected from nitrogen, oxygen, P(O)m and S(O)n (wherein m and n are integers from 0 to 2) heteroatoms, but excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. The heterocyclic group preferably has 3 to 12 ring atoms (i.e., a 3-12-membered heterocyclic group), wherein 1-4 heteroatoms are selected from N, O and S atoms, more preferably has 3 to 8 ring atoms (i.e., a 3-8-membered heterocyclic group), wherein 1-4, 1-3 or 1-2 heteroatoms are selected from N, O and S atoms, further preferably has 5 to 8 ring atoms (i.e., a 5-8-membered heterocyclic group), wherein 1-4, 1-3 or 1-2 heteroatoms are selected from N, O and S atoms, and most preferably has 5 to 6 ring atoms (i.e., a 5-6-membered heterocyclic group), wherein 1-4, 1-3 or 1-2 heteroatoms are selected from N, O and S atoms. Non-limiting examples of the monocyclic heterocyclic group include: azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, piperidinyl, piperazinyl, morpholinyl, 1,3-dioxolane, 2,2-difluoro-1,3-dioxolane, cyclopentane 1-one, 2,2-difluorocyclopentane 1-one, azepanyl, oxolanyl or azacyclopentanyl, etc. Non-limiting examples of the polycyclic heterocyclic group include: spiroheterocyclic group, fused heterocyclic group and bridged heterocyclic group.
[0104] The heterocyclic group can be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is the heterocyclic group.
[0105] The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclic, aryl or heteroaryl.
[0106] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group having a conjugated electron system. The term "aryl" can be used interchangeably with the term "aromatic ring" or "aromatic ring". Examples of aryl groups include 6-14 membered aryl (i.e., C 6-14 Aryl), 6-10 membered aryl (i.e. C6-10 The aryl group may be optionally substituted by one or more substituents described in the present invention.
[0107] The aryl group may be fused to a heteroaryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is an aryl ring. The aryl group may be optionally substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups, which are independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, sulfhydryl, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclic, aryl or heteroaryl.
[0108] The term "heteroaryl" refers to a monocyclic heteroaryl group (i.e., a monocyclic heteroaryl) or a fused polycyclic heteroaryl group (i.e., a polycyclic heteroaryl) having a conjugated π electron system, which has 5 to 14 (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14) ring atoms (i.e., a 5-14-membered heteroaryl), wherein one or more (e.g., 1, 2, 3, or 4) ring atoms are heteroatoms selected from nitrogen, oxygen, P(O)m, and S(O)n (wherein m and n are integers of 0-2), preferably heteroatoms selected from nitrogen, oxygen, or sulfur, but excluding the ring part of -OO-, -OS-, or -SS-, and the remaining ring atoms are carbon. The heteroaryl group is preferably a heteroaryl group having 5 to 10 ring atoms (i.e., a 5-10-membered heteroaryl). The monocyclic heteroaryl group is preferably a heteroaryl group having 5 to 6 ring atoms (i.e., a 5-6 membered heteroaryl group), and non-limiting examples include: furanyl, pyranyl, thienyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridonyl, pyrazinyl, pyridazinyl, and the like. The polycyclic heteroaryl group is preferably a 5-6-membered heteroaryl and a 5-6-membered heteroaryl, a 5-10-membered heteroaryl and a C6-10 aryl, or a C6-10 aryl and a 5-10-membered heteroaryl, and is further preferably a 5-6-membered heteroaryl and a 5-6-membered heteroaryl, a 5-6-membered heteroaryl and a phenyl, or a phenyl and a 5-6-membered heteroaryl. Non-limiting examples include: indolyl, indazolyl, quinolyl, isoquinolyl, quinoxalinyl, phthalazinyl, benzimidazolyl, benzothienyl, thienophenyl, quinazolinyl, benzothiazolyl, carbazolyl, thienopyridyl, pyridothiphenyl, pyridopyrrolyl, and the like.
[0109] The heteroaryl group may be fused to an aryl, heterocyclic or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring. The heteroaryl group may be optionally substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups, which are independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, sulfhydryl, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclic, aryl or heteroaryl.
[0110] The term "alkoxy" refers to -O-(alkyl) or -O-(unsubstituted cycloalkyl), wherein alkyl and cycloalkyl are as defined above, and have 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) carbon atoms (i.e., C1-10 alkoxy). The alkoxy preferably has an alkoxy of 1 to 8 carbon atoms (i.e., C1-8 alkoxy), more preferably an alkoxy of 1 to 6 carbon atoms (i.e., C1-6 alkoxy), and most preferably an alkoxy of 1 to 3 carbon atoms (i.e., C1-3 alkoxy). Non-limiting examples include: methoxy, ethoxy, propoxy, butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc. The alkoxy group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, mercapto, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0111] The term "alkylthio" refers to -S-(alkyl) or -S-(unsubstituted cycloalkyl), wherein alkyl and cycloalkyl are as defined above, and have 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) carbon atoms (i.e., C1-10 alkylthio). The alkylthio is preferably an alkylthio having 1 to 8 carbon atoms (i.e., C1-10 alkylthio). 1-8 alkylthio), more preferably alkylthio having 1 to 6 carbon atoms (i.e., C 1-6 The term "alkylthio" refers to an alkylthio group (i.e., C1-3 alkylthio) having 1 to 3 carbon atoms. Non-limiting examples include methylthio, ethylthio, propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, etc. The alkylthio group may be optionally substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably one or more of the following groups independently selected from deuterium, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, halogen, sulfhydryl, hydroxyl, nitro, amino, cyano, carboxyl, oxo, cycloalkyl, heterocyclyl, aryl or heteroaryl.
[0112] The term "halo" or "halogen" or "halo" is understood to mean a fluorine (F), chlorine (Cl), bromine (Br) or iodine (I) atom, preferably a fluorine, chlorine or bromine atom.
[0113] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above. Non-limiting examples include: fluoromethyl, chloromethyl, bromomethyl, iodomethyl, difluoromethyl, chlorofluoromethyl, dichloromethyl, bromofluoromethyl, trifluoromethyl, chlorodifluoromethyl, dichlorofluoromethyl, trichloromethyl, bromodifluoromethyl, bromochlorofluoromethyl, dibromofluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2,2-difluoroethyl, 2-chloro-2-fluoroethyl, 2,2-dichloroethyl, 2-bromo-2-fluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2, 2,2-trichloroethyl, 2-bromo-2,2-difluoroethyl, 2-bromo-2-chloro-2-fluoroethyl, 2-bromo-2,2-dichloroethyl, 1,1,2,2-tetrafluoroethyl, pentafluoroethyl, 1-chloro-1,2,2,2-tetrafluoroethyl, 2-chloro-1,1,2,2-tetrafluoroethyl, 1,2-dichloro-1,2,2-trifluoroethyl, 2-bromo-1,1,2,2-tetrafluoroethyl and the like, preferably fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl and 2,2-difluoroethyl.
[0114] The term "heteroatom" refers to oxygen (O), sulfur (S) or nitrogen (N), including nitrogen (N) and sulfur (S) in any oxidation state; primary, secondary, tertiary amines and quaternary ammonium salts; or a form in which the hydrogen on the nitrogen atom in a heterocyclic ring is substituted, for example: N, NH, NR.
[0115] The term "hydrogen (H)" refers to a single hydrogen atom, which may be attached to other groups, such as an oxygen atom, to form a hydroxyl group.
[0116] The term "thiol" refers to -SH.
[0117] The term "hydroxy" refers to -OH.
[0118] The term "nitro" refers to -NO2.
[0119] The term "amino" refers to -NH2.
[0120] The term "cyano" refers to -CN.
[0121] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium, wherein alkyl is as defined above.
[0122] For example, the expression "C1-C6" or "C 1-6" covers the range of 1-6 carbon atoms, and should be understood to also cover any sub-ranges and each point value therein, such as C1-C5, C3-C4, C2-C6, C3-C6, C4-C5, C4-C6, C2-C4, etc., as well as C1, C2, C3, C4, C5, C6, etc. For another example, the expression "C1-C5" or "C 1-5 " covers a range of 1-5 carbon atoms and should be understood to also cover any subranges and each point value therein, such as C2-C5, C3-C4, C1-C2, C1-C3, C1-C4, C1-C5, etc., as well as C1, C2, C3, C4, C5, etc. For another example, the expression "C2-C5" or "C 2-5 " covers the range of 2-5 carbon atoms, and should be understood to also cover any sub-ranges and each point value therein, such as C2-C5, C3-C4, C2-C3, C2-C4, C3-C5, C4-C5, etc., as well as C2, C3, C4, C5, etc. For another example, the expression "three-membered to eight-membered" should be understood to cover any sub-ranges and each point value therein, such as three-membered to five-membered, three-membered to six-membered, three-membered to seven-membered, three-membered to eight-membered, four-membered to five-membered, four-membered to six-membered, etc., as well as three, four, five, six, etc. Other similar expressions in this article should also be understood in a similar manner.
[0123] The terms "include", "comprising", "having", "containing" or "involving" and other variations thereof herein are inclusive or open-ended and do not exclude other unlisted elements or method steps. Those skilled in the art will appreciate that the above terms such as "comprising" encompass the meaning of "consisting of".
[0124] The term "one or more" or the similar expression "at least one" may mean, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
[0125] The term "selected from..." means that one or more elements in the group listed later are independently selected and may include combinations of two or more elements.
[0126] The term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.
[0127] When it is stated that each carbon atom in a group may be optionally replaced by a heteroatom, provided that the normal valencies of all atoms in the group in the present instance are not exceeded and that a stable compound is formed.
[0128] In the compounds mentioned in the present invention, hydrogen atoms may be partially or completely replaced by deuterium. Specifically, the term "deuterated substance" means that hydrogen atoms of the compounds of the present invention may be partially or completely replaced by deuterium.
[0129] The term "pharmaceutically acceptable salt" refers to an organic salt or an inorganic salt of a compound of the present invention.
[0130] The term "pharmaceutically acceptable carrier" refers to those substances that have no significant irritation to organisms and do not impair the biological activity and performance of the active compound. "Pharmaceutically acceptable carrier" includes, but is not limited to, glidants, sweeteners, diluents, preservatives, dyes / colorants, flavoring agents, surfactants, wetting agents, dispersants, disintegrants, stabilizers, solvents or emulsifiers.
[0131] The term "administration" or "administering" refers to a method that enables a compound or composition to be delivered to a desired biological site of action. These methods include, but are not limited to, oral or parenteral (including intraventricular, intravenous, subcutaneous, intraperitoneal, intramuscular, intravascular injection or infusion), topical, rectal administration, etc. In particular, injection or oral administration.
[0132] As used herein, the term "treat" includes alleviating, reducing or ameliorating a disease or symptom, preventing other symptoms, ameliorating or preventing the underlying metabolic factors of a symptom, inhibiting a disease or symptom, for example, preventing the disease or symptom from developing, alleviating a disease or symptom, promoting remission of a disease or symptom, or stopping the symptoms of a disease or symptom, and extends to include prevention. "Treatment" also includes achieving a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit refers to the eradication or improvement of the condition being treated. In addition, a therapeutic benefit is achieved by eradicating or improving one or more physiological signs associated with the underlying disease, and although the patient may still suffer from the underlying disease, an improvement in the patient's disease can be observed. A prophylactic benefit refers to the use of the composition by a patient to prevent the risk of a certain disease, or when a patient takes it when one or more physiological symptoms of a disease occur, although the disease has not yet been diagnosed.
[0133] The term "active ingredient", "therapeutic agent", "active substance" or "active agent" refers to a chemical entity that is effective in treating or preventing a target disorder, disease or condition. The term "neuropsychiatric disease" refers to a general term for neurological diseases and psychiatric diseases, including neurological diseases and / or psychiatric diseases.
[0134] With respect to a drug, drug unit or active ingredient, the term "effective amount", "therapeutically effective amount" or "prophylactically effective amount" refers to a sufficient amount of the drug or pharmaceutical agent that can achieve the desired effect with acceptable side effects. The determination of the effective amount varies from person to person, depending on the age and general condition of the individual and on the specific active substance. The appropriate effective amount in each case can be determined by a person skilled in the art based on routine experiments.
[0135] As used herein, "individual" includes humans or non-human animals. Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals. "Non-human animals" in the present invention include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and / or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
[0136] The term "room temperature" refers to a temperature from 10°C to 40°C. In some embodiments, "room temperature" refers to a temperature from 15°C to 30°C; in other embodiments, "room temperature" refers to a temperature from 18°C to 25°C.
[0137] "Equivalent" or its abbreviation "eq" refers to the equivalent amount of other raw materials required based on the equivalent relationship of chemical reactions, with the basic raw material used in each step as the benchmark (1 equivalent).
[0138] In the context of the present invention, when or whether the words "about" or "approximately" are used, they mean within 10%, suitably within 5%, and especially within 1% of a given value or range. Alternatively, for a person of ordinary skill in the art, the term "about" or "approximately" means within an acceptable standard error range of the mean. Whenever a number having a value of N is disclosed, any number having a value within N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8% or N+ / -10% will be explicitly disclosed, where "+ / -" means plus or minus.
[0139] Beneficial technical effects of the present invention
[0140] Compared with the prior art, the technical solution of the present invention has the following advantages:
[0141] The tricyclic derivatives of the present invention may have stronger effects, wider indications, faster onset and less neurotoxic side effects as 5-HT and NA reuptake inhibitors and / or 5-HT1A receptor agonists or antagonists in the treatment of neuropsychiatric diseases than the antidepressants with a single mechanism of action currently used in clinical practice, such as clomipramine, desipramine, fluoxetine, and antidepressants with a dual mechanism of action, such as venlafaxine and duloxetine. DETAILED DESCRIPTION
[0142] Unless otherwise indicated or there is an obvious conflict in the context, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the invention belongs. If there is a conflict, the definitions provided in the application shall prevail. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient. All patents, published patent applications and publications cited herein are incorporated herein by reference.
[0143] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially. If not otherwise specified, the ratios or percentages used herein are by weight.
[0144] The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and / or liquid chromatography-mass spectrometry (LC-MS).
[0145] NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements were performed using a Bruker Advanced 400 NMR spectrometer, with deuterated dimethyl sulfoxide (DMSO-d6) or deuterated chloroform (Chloroform-d) as the solvent and tetramethylsilane (TMS) as the internal standard.
[0146] Liquid chromatography-mass spectrometry (LC-MS) was performed using a Shimadzu LCMS2020 liquid mass spectrometer.
[0147] Agilent 1260 liquid chromatograph was used for HPLC measurement.
[0148] The thin layer chromatography silica gel plate uses Qingdao Ocean Chemical silica gel plate. The specification used for TLC is 0.2mm-0.25mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.
[0149] General synthetic route of the compounds of the present invention:
[0150] Iminodibenzyl or 3-chloroiminodibenzyl is dissolved in toluene, and a toluene solution of chloroacyl chloride or bromochloroalkane is added at room temperature to react to obtain a tricyclic chloro compound, which undergoes a substitution reaction with an aryl piperazine (or piperidine) in N,N-dimethylformamide under the action of potassium carbonate and potassium iodide to obtain a target compound, and the free base of the target compound reacts with a corresponding acid to obtain a salt of the target compound.
[0151] Example 1 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propane
[0152] Alkane-1-one oxalate (1)
[0153]
[0154] 1.1 Preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one
[0155] Sequentially add iminodibenzyl (9.76g, 0.05mol) and toluene (200mL) into a 500mL single-necked flask, stir with magnetic force, slowly drop 3-chloropropionyl chloride (12.7g, 0.1mol) at room temperature, transfer to an oil bath after the dropwise addition, heat to 110°C, and react for 2.5h. After the reaction, remove toluene by vacuum distillation, add 100mL of saturated sodium bicarbonate, then add 200mL of dichloromethane for extraction, extract the aqueous phase with dichloromethane twice (2×150mL), combine the organic phases, wash with saturated sodium bicarbonate solution twice (2×200mL), dry with anhydrous magnesium sulfate, filter, and concentrate to obtain the product with a yield of 79.48%.
[0156] 1.2 Preparation of 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate
[0157] 3-Chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one (2 g, 0.007 mol), potassium carbonate (9.67 g, 0.014 mol), potassium iodide (0.58 g, 0.0035 mol), 2,3-dichlorophenylpiperazine hydrochloride (1.87 g, 0.0064 mol) and N,N-dimethylformamide (100 mL) were added into a 100 mL single-necked flask in sequence, stirred magnetically, heated to 90°C, and reacted for 10 hours. After the reaction, the reaction solution was filtered, and the filtrate was directly poured into a 500 mL separatory funnel, and 200 mL of water and 200 mL of ethyl acetate were added for extraction. The aqueous phase was extracted twice with ethyl acetate (2×100 mL), and the organic phases were combined, washed twice with saturated sodium chloride solution (2×150 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was separated by silica gel column chromatography (DCM / MeOH=50:1) to obtain a light yellow oily liquid, which was then salified with ethyl acetate solution of oxalic acid to obtain the product. The yield was 62.3%. 1H NMR (400MHz, DMSO-d6) δ7.49(d,J=6.9Hz,1H),7.34(td,J=11.7,7.3Hz,6H),7.21(d,J=3.3Hz,3H),7.16(dd,J=6.8, 2.9Hz,1H),3.40–3.27(m,2H),3.22–3.02(m,8H),2.86-2.75(m,4H),2.50–2.39(m,2H); MS(ESI,m / z):480.15(M+H) + .
[0158] Example 2 3-[4-(Benzo[b]thiophen-4-yl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (2)
[0159]
[0160] 2.1 Preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one The preparation method was as described in 1.1 of Example 1.
[0161] 2.2 According to the method of 1.2 in Example 1, 1-(benzothiophen-4-yl)piperazine hydrochloride was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 50.1%. 1 H NMR (400MHz, DMSO-d6) δ7.74(d,J=5.5Hz,1H),7.67(d,J=8.1Hz,1H),7.51(d,J=7.1Hz,1H),7.45(d,J=5.6Hz,1H),7.32(dq,J=15.4,8.1Hz,5H) ,7.22(s,3H),6.92(d,J=7.7Hz,1H),3.43–3.31(m,2H),3.23-3.05(m,8 H),2.96–2.70(m,4H),2.51((t,J=7.0Hz,2H); MS(ESI,m / z):468.2(M+H) + ;
[0162] Example 3 3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepine-5-yl]
[0163] [3] Propane-1-one oxalate
[0164]
[0165] 3.1 Preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one The preparation method was as described in 1.1 of Example 1.
[0166] 3.2 According to the method of 1.2 in Example 1, 4-(1,2-benzisothiazol-3-yl)-1-piperazine was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 56.6%. 1 H NMR (400MHz, DMSO-d6) δ8.09(d,J=8.3Hz,2H),7.58(t,J=7.6Hz,1H),7.47(dt,J=15.2,7.4Hz,2H),7.41–7.25(m,5H),7.23-7.1 7(m,3H),3.41–3.27(m,2H),3.22-2.97(m,8H),2.81(dh,J=21.1,7.6,5.8Hz,4H),2.51–2.39(m,2H);MS(ESI,m / z):469.2(M+H) + ;
[0167] Example 4 3-[3,4-dihydroisoquinolin-2(1H)2-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (4)
[0168]
[0169] 4.1 Preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one The preparation method was as described in 1.1 of Example 1.
[0170] 4.2 According to the method of 1.2 in Example 1, 1,2,3,4-tetrahydroisoquinoline was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 47.8%. 1 H NMR (400MHz, DMSO-d6) δ7.49(d,J=7.4Hz,1H),7.31(dd,J=14.1,6.9Hz,4H),7.21(d,J=3.8Hz,6H),7.11(d,J=7.0Hz,1H),4.13(s,2H),3 .29(td,J=15.6,14.1,6.4Hz,6H),2.98(t,J=6.7Hz,2H),2.76(dq,J=11.9,6.6,5.8Hz,2H),2.62–2.51(m,2H); MS(ESI,m / z):383.2(M+H) + ;
[0171] Example 5 3-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]
[0172] [5-Azepin-5-yl]propan-1-one oxalate (5)
[0173]
[0174] 5.1 Preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one The preparation method was as described in 1.1 of Example 1.
[0175] 5.2 According to the method of 1.2 in Example 1, 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole hydrochloride was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 49.1%. 1 H NMR (400 MHz, DMSO-d6)δ
[0176] 8.08(dd,J=9.2,5.0Hz,1H),7.72(d,J=9.0Hz,1H),7.51(d,J=7.1Hz,1H),7.33(p,J=
[0177] 10.1,9.1Hz,6H),7.21(d,J=3.7Hz,3H),3.41–3.14(m,6H),3.00(q,J=10.3,8.0Hz,4H),2.81(dq,J =15.4,10.1,8.1Hz,3H),2.19(d,J=13.5Hz,2H),2.10(d,J=13.2Hz,2H); MS(ESI,m / z):470.2(M+H) + .
[0178] Example 6 Preparation of 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (6)
[0179]
[0180] 6.1 Preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one
[0181] According to the method of 1.1 in Example 1, 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 3-chloropropionyl chloride to obtain the product with a yield of 76.12%.
[0182] 6.2 Preparation of 3-[4-(2,3-dichlorophenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate
[0183] According to the method of 1.2 in Example 1, 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was reacted with 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 65.21%. 1 H NMR (400MHz, DMSO-d6) δ7.71 (s, 1H), 7.54 (d, J = 7.3Hz, 1H), 7.45 (d, J = 7.8Hz, 1H), 7.38 (d, J = 8.4Hz, 2H), 7.29 (d, J = 5.0Hz, 2H), 7.23 (d, J = 9. 1Hz,2H),7.17-7.13(m,1H),3.29–3.24(m,2H),3.14–3.10(m,8H),2.84–2.78(m,4H),2.42(dd,J=16.7,8.0Hz,2H); MS(ESI,m / z):514.1(M+H) + .
[0184] Example 7 Preparation of 3-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (7)
[0185]
[0186] 7.1 Preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 6.1 of Example 6.
[0187] 7.2, according to the method of 6.2 in Example 6, 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product in a yield of 61.2%. 1H NMR (400MHz, DMSO-d6) δ8.07(dd,J=8.7,5.3Hz,1H),7.72(d,J=9.1Hz,1H),7.57(d,J=7.3 Hz,1H),7.46(s,1H),7.39(d,J=8.7Hz,1H),7.36–7.27(m,3H),7.24(d,J=9.4Hz,2H),3.4 8–3.34(m,4H),3.28(dd,J=13.1,7.1Hz,4H),2.97(tt,J=17.6,7.5Hz,3H),2.80(tt,J=15 .4,6.1Hz,2H),2.19(d,J=13.1Hz,2H),2.10(t,J=12.6Hz,2H); MS(ESI,m / z):504.2(M+H) + .
[0188] Example 8 Preparation of 3-[3,4-dihydroisoquinolin-2(1H)-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (8)
[0189]
[0190] 8.1 Preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one The preparation method was the same as that in Example 6, 6.1.
[0191] 8.2, according to the method of 6.2 in Example 6, 1,2,3,4-tetrahydroisoquinoline was used to replace 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product with a yield of 58.4%. 1 H NMR (400MHz, DMSO-d6) δ7.73(s,1H),7.56(d,J=7.5Hz,1H),7.47(s,1H),7.39–7.34(m,3H),7.22(d,J=5.9Hz,4H),7.15(d,J=6.9Hz,1H),4.28(d ,J=7.6Hz,2H),3.30–3.23(m,2H),3.03(d,J=15.1Hz,4H),2.78(tt,J=15.1,5.6Hz,4H),2.57(dt,J=14.9,8.5Hz,2H); MS(ESI,m / z):417.2(M+H) + .
[0192] Example 9 Preparation of 3-[4-(Benzo[b]thiophen-4-yl)piperazine-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (9)
[0193]
[0194] 9.1 Preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 6.1 in Example 6.
[0195] 9.2 According to the method of 6.2 in Example 6, 1-(benzothiophen-4-yl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product with a yield of 59.7%. 1 H NMR (400MHz, DMSO-d6) δ8.76 (s, 1H), 8.09 (s, 1H), 7.71 (d, J = 5.7Hz, 2H), 7.6 5(d,J=8.0Hz,2H),7.49(d,J=5.6Hz,2H),7.28(t,J=7.9Hz,2H),6.91(d,J=7 .6Hz,2H),3.61(dd,J=11.3,5.5Hz,6H),3.42–3.29(m,2H),3.25(t,J=5.1Hz ,2H),3.06(t,J=5.0Hz,3H),3.00(t,J=5.1Hz,3H); MS(ESI,m / z):502.2(M+H) + .
[0196] Example 10 Preparation of 3-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (10)
[0197]
[0198] 10.1 The preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,ff]azepin-5-yl)propan-1-one was carried out according to the preparation method of 6.1 in Example 6.
[0199] 10.2 According to the method of 6.2 in Example 6, 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product with a yield of 48.1%. 1H NMR (400MHz, DMSO-d6) δ8.09(d,J=8.2Hz,1H),7.73(s,1H),7.57(q,J=6.7,5.5Hz,2H),7.46(d,J=6.6Hz,2H),7.41–
[0200] 7.30(m,3H),7.25(d,J=18.5Hz,2H),3.74–3.45(m,4H),3.37-3.25(m,2H),3.13(dd, J=28.8,9.3Hz,4H),2.95-2.62(m,4H),2.47-2.32(m,2H); MS(ESI,m / z):503.2(M+H) + .
[0201] Example 11 Preparation of 4-[4-(Benzothiophene-4-yl)piperazine-1-yl]-1-[10,11-dihydro-5H-diphenyl[b,f]azepin-5-yl]butane-1-one oxalate (11)
[0202]
[0203] 11.1 Preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one
[0204] According to the method of step 1.1 in Example 1, 4-chlorobutyryl chloride was used instead of 3-chloropropionyl chloride to obtain the product with a yield of 83.7%.
[0205] 11.2 According to the method of 1.2 in Example 1, 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was reacted with 1-(benzothiophen-4-yl)piperazine hydrochloride to obtain the product in a yield of 46.9%. 1 H NMR (400MHz, DMSO-d6) δ7.75(d,J=5.4Hz,1H),7.68(d,J=8.0Hz,1H),7.50–7.44(m,2H),7.31(q,J=10.9,8.1Hz,5H),7.20(s,3H),6.93(d, J=7.6Hz,1H),3.21(s,8H),2.99(s,3H),2.80(tt,J=14.4,6.2Hz,3H),2.07(d,J=17.7Hz,2H),1.94-1.90(m,2H); MS(ESI,m / z):482.2(M+H) + .
[0206] Example 12 Preparation of 4-[4-(2,3-dichlorophenyl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (12)
[0207]
[0208] 12.1 Preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one The preparation method was the same as that of Example 11.1.
[0209] 12.2 According to the method of 11.2 in Example 11, 1-(2,3-dichlorophenyl)piperazine hydrochloride was used to replace 1-(benzothiophen-4-yl)piperazine hydrochloride to obtain the product with a yield of 43.1%. 1 H NMR(400MHz,DMSO-d6)δ7.31–
[0210] 7.28(m,2H),7.26(d,J=7.4Hz,1H),7.23–7.18(m,5H),6.96–6.91(m,3H),3.08(t,J=7.0Hz,4H),2.97(d,J=0.6Hz,4H) ,2.68(t,J=7.1Hz,4H),2.57(t,J=7.1Hz,2H),2.51(t,J=7.1Hz,2H),1.88(p,J=7.0Hz,2H); MS(ESI,m / z):495.2(M+H) + .
[0211] Example 13 Preparation of 4-[4-(2,3-dichlorophenyl)piperazine-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (13)
[0212]
[0213] 13.1 According to the method of 1.1 in Example 1, 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 4-chlorobutyryl chloride to obtain the product with a yield of 80.46%.
[0214] 13.2 According to the method of 1.2 in Example 1, 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was reacted with 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 51.71%. 1HNMR (400MHz, DMSO-d6) δ7.69 (s, 1H), 7.51 (d, J = 7.4Hz, 2H), 7.45 (d, J = 10.9Hz, 2H), 7.24–7.20 (m, 3H), 7.15 (d, J = 7. 4Hz,2H),3.11(d,J=42.9Hz,8H),2.98–2.90(m,4H),2.85–2.72(m,4H),2.09–1.98(m,2H); MS(ESI,m / z):528.2(M+H) +
[0215] Example 14 Preparation of 4-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]-butane-1-one oxalate (14)
[0216]
[0217] 14.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0218] 14.2 According to the method of 13.2 in Example 13, 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 43.11%. 1 H NMR (400MHz, DMSO-d6) δ8.07(s,1H),7.72(t,J=7.6Hz,2H),7.53(d,J=7.3Hz,1H),7.44(s,1H),7.39(d,J=6.1Hz,2H),7.23(d,J=8 .8Hz,3H),3.57–3.37(m,5H),2.99(s,4H),2.87–2.73(m,4H),2.21(d,J=13.3Hz,2H),2.14–2.02(m,4H); MS(ESI,m / z):518.2(M+H) +
[0219] Example 15 Preparation of 4-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (15)
[0220]
[0221] 15.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0222] 15.2 According to the method of 13.2 in Example 13, 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 39.61%. 1 H NMR (400MHz, DMSO-d6) δ8.10(t,J=9.0Hz,2H),7.58(t,J=7.6Hz,1H),7.52(d,J=7 .3Hz,1H),7.46(d,J=8.9Hz,2H),7.37(d,J=6.1Hz,1H),7.30(dd,J=15.3,7.8Hz,2 H),7.21(d,J=7.2Hz,2H),3.85–3.47(m,6H),3.30–3.18(m,6H),2.98-2.88(m,2H ),2.85–2.74(m,2H),2.06(dq,J=16.3,8.6,6.7Hz,2H); MS(ESI,m / z):517.2(M+H) + .
[0223] Example 16 Preparation of 4-[4-(pyrimidin-2-yl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (16)
[0224]
[0225] 16.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0226] 16.2 According to the method of 13.2 in Example 13, 2-(piperazin-1-yl)pyrimidine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain a product yield of 42.37%. 1H NMR (400MHz, DMSO-d6) δ8.42(d,J=4.8Hz,2H),7.69(s,1H),7.51(d,J=7.3Hz,1H),7.43( s,1H),7.39–7.32(m,2H),7.21(d,J=7.8Hz,2H),6.72(t,J=4.8Hz,1H),4.00–3.85(m,4H) ,3.25(td,J=18.9,17.8,9.8Hz,2H),3.06(s,4H),2.91(t,J=8.0Hz,2H),2.78(dt,J=21. 1,10.6Hz,2H),2.44(s,2H),2.04(dq,J=16.2,8.7,6.8Hz,2H); MS(ESI,m / z):462.2(M+H) + .
[0227] Example 17 Preparation of 4-[3,4-dihydroisoquinolin-2(1H)-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (17)
[0228]
[0229] 17.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0230] 17.2 According to the method of 13.2 in Example 13, using 1,2,3,4-tetrahydroisoquinoline instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride, the product was obtained with a yield of 44.67%. 1 H NMR (400MHz, DMSO-d6) δ7.69(s,1H),7.51(d,J=7.5Hz,1H),7.43(s,1H),7.36(d,J=7.0Hz,2H),7.28(s,2H),7.22(d,J=2.9Hz,3H),7.16(d,J=7. 5Hz,1H),4.21(s,2H),3.22(h,J=8.2,6.9Hz,4H),3.01(d,J=6.2Hz,4H), 2.78(q,J=8.6,6.7Hz,4H),2.07–1.99(m,2H); MS(ESI,m / z):431.2(M+H) + .
[0231] Example 18 Preparation of 4-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (18)
[0232]
[0233] 18.1 According to the method of 1.1 in Example 1, 4-chlorobutyryl chloride was used to replace 3-chloropropionyl chloride to obtain the product with a yield of 82.13%.
[0234] 18.2 According to the method of 1.2 in Example 1, 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was reacted with 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole to obtain the product in a yield of 40.27%. 1 HNMR(400MHz,DMSO-d6)δ8.08(dd,J=8.8,5.3Hz,1H),7.73(d,J=9.1Hz,1H),7.47(d,J=7.4Hz,1 H),7.36(t,J=8.0Hz,2H),7.29(d,J=7.9Hz,3H),7.20(s,3H),3.46(d,J=22.6Hz,2H),3.35–3.21 (m,2H),3.00(q,J=9.4,7.9Hz,4H),2.81(tq,J=14.9,7.3,6.7Hz,3H),2.20(d,J=10.9Hz,2H),2. 12(d,J=12.3Hz,2H),2.10–1.99(m,2H),1.92(dt,J=13.1,6.4Hz,2H); MS(ESI,m / z):484.2(M+H) + .
[0235] Example 19 Preparation of 4-[4-(pyrimidin-2-yl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (19)
[0236]
[0237] 19.1 The preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 18.1 in Example 18.
[0238] 19.2 According to the method of 18.2 in Example 18, using 2-(piperazin-1-yl)pyrimidine hydrochloride to replace 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, the product was obtained in a yield of 49.80%. 1 H NMR (400MHz, DMSO-d6) δ8.41(d,J=4.7Hz,2H),7.46(d,J=7.4Hz,1H),7.34(dd,J=14.1,7. 3Hz,2H),7.29(d,J=6.9Hz,2H),7.20(s,3H),6.72(t,J=4.8Hz,1H),3.88(s,4H),3.27(dd d,J=21.2,12.7,6.2Hz,2H),2.99(s,4H),2.85(d,J=7.8Hz,2H),2.78(dt,J=14.7,6.7Hz, 2H), 2.05 (dt, J=16.1, 7.0Hz, 2H), 1.87 (dt, J=12.4, 6.2Hz, 2H); MS (ESI, m / z): 428.2 (M+H) + .
[0239] Example 20 Preparation of 4-[3,4-dihydroisoquinolin-2(1H)-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (20)
[0240]
[0241] 20.1 The preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 18.1 in Example 18.
[0242] 20.2 According to the method of 18.2 in Example 18, replacing 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole with 1,2,3,4-tetrahydroisoquinoline, the product was obtained in a yield of 38.22%. 1H NMR (400MHz, DMSO-d6) δ7.46(d,J=7.5Hz,1H),7.35(d,J=7.6Hz,1H),7.30(d,J=7.8 Hz,2H),7.25(d,J=9.4Hz,2H),7.21(d,J=11.7Hz,3H),7.17(d,J=7.8Hz,3H),4.23(s ,2H),3.32–3.15(m,4H),3.02(dt,J=11.8,6.9Hz,4H),2.77(dq,J=14.7,7.4,6.9Hz ,2H),2.07(dt,J=15.6,6.9Hz,2H),1.96(t,J=7.9Hz,2H); MS(ESI,m / z):397.2(M+H) + .
[0243] Example 21 Preparation of 4-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one oxalate (21)
[0244]
[0245] 21.1 The preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 18.1 in Example 18.
[0246] 21.2 According to the method of 18.2 in Example 18, using 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride to replace 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, the product was obtained in a yield of 40.20%. 1 H NMR (400MHz, DMSO-d6) δ8.10(t,J=8.4Hz,2H),7.58(t,J=7.6Hz,1H),7.47(d,J=7.7H z,2H),7.36(d,J=7.2Hz,1H),7.30(p,J=6.9Hz,3H),7.20(d,J=3.4Hz,3H),3.64(s,4H ),3.36–3.16(m,6H),2.95(t,J=7.8Hz,2H),2.80(tq,J=14.9,6.1Hz,2H),2.48(s,1H ), 2.07 (dt, J=15.9, 7.1Hz, 1H), 1.90 (h, J=7.3, 6.8Hz, 2H); MS (ESI, m / z): 483.2 (M+H) + .
[0247] Example 22 Preparation of 4-[4-(2-methoxyphenyl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (22)
[0248]
[0249] 22.1 The preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 18.1 in Example 18.
[0250] 22.2 According to the method of 18.2 in Example 18, using 1-(2-methoxyphenyl)piperazine hydrochloride to replace 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, the product was obtained in a yield of 40.91%. 1 H NMR (400MHz, DMSO-d6) δ7.47(d,J=7.3Hz,1H),7.36(d,J=7.3Hz,1H),7.31(q,J=7.4Hz,3H ),7.20(d,J=3.5Hz,3H),6.99(dt,J=13.1,5.4Hz,2H),6.90(d,J=4.1Hz,2H),3.78(s,3H) ,3.37–3.18(m,4H),3.15(s,4H),2.94(t,J=7.9Hz,2H),2.80(td,J=12.7,10.7,5.6Hz,2H ),2.46(t,J=7.2Hz,2H),2.15–1.97(m,2H),1.95–1.84(m,2H); MS(ESI,m / z):456.2(M+H) + .
[0251] Example 23 Preparation of 4-[4-(2-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (23)
[0252]
[0253] 23.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0254] 23.2 According to the method of 13.2 in Example 13, using 1-(2-methoxyphenyl)piperazine hydrochloride instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride, the product was obtained with a yield of 36.28%. 1H NMR (400MHz, DMSO-d6) δ7.70 (s, 1H), 7.51 (d, J = 7.3Hz, 1H), 7.47–7.43 (m, 1H), 7.37 (d, J = 6. 4Hz,1H),7.32(s,1H),7.27–7.19(m,3H),6.98(d,J=4.9Hz,1H),6.89(d,J=4.3Hz,2H),3.78( s,3H),3.29(d,J=33.6Hz,4H),2.96(t,J=7.7Hz,4H),2.79(dq,J=20.1,13.3,10.0Hz,4H),2 .50–2.34(m,2H),2.13–1.96(m,2H),1.91(dd,J=14.3,7.3Hz,2H);MS(ESI,m / z):490.2(M+H) + .
[0255] Example 24 Preparation of 4-[4-(3-methoxyphenyl)piperazine-1-yl]-1-10,1[1-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (24)
[0256]
[0257] 24.1 The preparation of 4-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 18.1 in Example 18.
[0258] 24.2 According to the method of 18.2 in Example 18, using 1-(3-methoxyphenyl)piperazine hydrochloride to replace 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole, the product was obtained in a yield of 41.47%. 1H NMR (400MHz, DMSO-d6) δ7.46(d,J=7.4Hz,1H),7.36(d,J=7.4Hz,1H),7.30(t,J=7.6Hz,3H),7.20( s,3H),7.13(d,J=8.1Hz,1H),6.55(d,J=8.4Hz,1H),6.50(s,1H),6.46–6.39(m,1H),3.72(s,3H),3 .38–3.19(m,6H),3.09(s,4H),2.91(t,J=7.9Hz,2H),2.80(tq,J=14.0,6.9,6.4Hz,2H),2.49–2.38 (m,1H),2.04(dt,J=16.0,7.2Hz,1H),1.88(dq,J=14.3,7.6,6.8Hz,2H); MS(ESI,m / z):456.3(M+H) + .
[0259] Example 25 Preparation of 4-[4-(3-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]butan-1-one oxalate (25)
[0260]
[0261] 25.1 The preparation of 4-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)butan-1-one was carried out according to the preparation method of 13.1 in Example 13.
[0262] 25.2 According to the method of 13.2 in Example 13, using 1-(3-methoxyphenyl)piperazine hydrochloride instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride, the product was obtained with a yield of 38.08%. 1H NMR(400MHz, DMSO-d6)δ7.70(s,1H),7.51(d,J=7.4Hz,1H),7.45–7.41(m,1H),7.38(d,J=6.5Hz,1H),7.3 0(dt,J=12.2,7.2Hz,2H),7.21(s,1H),7.14(t,J=8.2Hz,1H),6.55(dd,J=8.2,2.4Hz,1H),6.49(d,J=2.4 Hz,1H),6.43(dd,J=8.0,2.4Hz,1H),3.72(s,3H),3.36–3.19(m,6H),3.08(s,4H),2.94–2.71(m,4H),2.4 9–2.36(m,1H),2.04(dq,J=16.2,9.9,6.8Hz,1H),1.89(dd,J=12.6,6.6Hz,2H); MS(ESI,m / z):490.2(M+H) + .
[0263] Example 26 Preparation of 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (26)
[0264]
[0265] 26.1 The preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 1.1 of Example 1.
[0266] 26.2 According to the method of 1.2 in Example 1, 1-(2-methoxyphenyl)piperazine hydrochloride was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 27.61%. 1 H NMR(400MHz, DMSO-d6)δ7.49(d,J=7.3Hz,1H),7.32(dp,J=14.9,7.4Hz,4H),7.21(s,3H),7.04–6.92(m,2H),6.89(d,J=4.3Hz,2H), 3.77(s,3H),3.42–3.23(m,3H),3.15(d,J=47.3Hz,8H),2.98–2.70(m,4H),2.45(dd,J=16.1,7.8Hz,1H); MS(ESI,m / z):442.2(M+H) + .
[0267] Example 27 Preparation of 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (27)
[0268]
[0269] 27.1 The preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 6.1 of Example 6.
[0270] 27.2 According to the method of 6.2 in Example 6, 1-(2-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product with a yield of 45.17%. 1 H NMR(400MHz,DMSO-d6)δ7.55(d,J=7.4Hz,1H),7.46(s,1H),7.39–7.23(m,5 H),7.02–6.94(m,2H),6.88(d,J=4.4Hz,2H),3.77(s,3H),3.35(dq,J=9.9,5 .1,4.5Hz,1H),3.29(dd,J=11.5,4.8Hz,1H),3.26–3.18(m,3H),3.10(s,8H) ,2.91–2.73(m,3H),2.43(dd,J=16.6,8.0Hz,1H);MS(ESI,m / z):476.2(M+H) + .
[0271] Example 28 Preparation of 3-[4-(3-methoxyphenyl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (28)
[0272]
[0273] 28.1 The preparation of 3-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 1.1 of Example 1.
[0274] 28.2 According to the method of 1.2 in Example 1, 1-(3-methoxyphenyl)piperazine hydrochloride was used instead of 2,3-dichlorophenylpiperazine hydrochloride to participate in the reaction to obtain the product with a yield of 48.22%. 1H NMR(400MHz,DMSO-d6)δ7.49(d,J=7.3Hz,1H),7.40–7.26(m,4H),7.21(s,3H),7.13(t,J =8.2Hz,1H),6.54(dd,J=8.3,2.3Hz,1H),6.48(d,J=2.4Hz,1H),6.42(dd,J=8.2,2.3Hz, 1H),3.72(s,3H),3.37(dd,J=12.6,7.6Hz,1H),3.28(h,J=7.0Hz,5H),3.15(t,J=7.1Hz, 2H),3.06–2.95(m,4H),2.92–2.71(m,3H),2.52–2.39(m,1H); MS(ESI,m / z):442.2(M+H) + .
[0275] Example 29 Preparation of 3-[4-(3-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]propan-1-one oxalate (29)
[0276]
[0277] 29.1 The preparation of 3-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-one was carried out according to the preparation method of 6.1 in Example 6.
[0278] 29.2 According to the method of 6.2 in Example 6, 1-(3-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to participate in the reaction to obtain the product with a yield of 40.35%. 1 H NMR(400MHz, DMSO-d6)δ7.55(d,J=7.3Hz,1H),7.45(s,1H),7.39–7.21(m,5H),7. 13(t,J=8.2Hz,1H),6.54(d,J=8.3Hz,1H),6.48(s,1H),6.42(d,J=8.2Hz,1H),3.7 2(s,3H),3.38–3.23(m,6H),3.17–3.09(m,2H),3.01(dd,J=10.5,5.1Hz,4H),2.7 9(tt,J=15.2,8.3Hz,3H),2.43(dt,J=15.6,7.2Hz,1H); MS(ESI,m / z):476.2(M+H) + .
[0279] Example 30 Preparation of 5-[4-(2,3-dichlorophenyl)piperazine-1-yl]-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one oxalate (30)
[0280]
[0281] 30.1 According to the method of 1.1 in Example 1, 5-chloropropionyl chloride was used instead of 3-chloropropionyl chloride to obtain the product with a yield of 70.57%.
[0282] 30.2 According to the method of 1.2 in Example 1, 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was reacted with 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 42.49%. 1 H NMR(400MHz,DMSO-d6)δ7.45(d,J=7.2Hz,1H),7.34(d,J=6.9Hz,3H),7.32–7.26 (m,3H),7.19(d,J=4.4Hz,4H),3.22(d,J=33.8Hz,10H),2.92(t,J=7.3Hz,2H),2. 79(tt,J=14.2,8.4Hz,2H),2.43(dd,J=16.2,7.9Hz,1H),2.04(dt,J=15.8,6.8Hz ,1H),1.64–1.57(m,2H),1.53(dd,J=14.8,7.3Hz,2H); MS(ESI,m / z):508.2(M+H) + .
[0283] Example 31 Preparation of 5-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (31)
[0284]
[0285] 31.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0286] 31.2 According to the method of 30.2 in Example 30, 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 39.95%. 1H NMR (400MHz, DMSO-d6) δ8.08(dd,J=8.8,5.2Hz,1H),7.72(dd,J=9.0,2.2Hz,1H),7.45(d,J=7.2Hz,1 H),7.39–7.32(m,2H),7.32–7.26(m,4H),7.19(d,J=4.1Hz,2H),3.47(d,J=12.0Hz,3H),3.27(td,J=2 0.9,19.6,10.7Hz,2H),3.04–2.94(m,4H),2.82(d,J=12.5Hz,2H),2.42(dd,J=15.5,7.4Hz,1H),2.2 6–2.10(m,4H),2.06(dd,J=15.9,8.5Hz,1H),1.59(dq,J=32.7,8.2Hz,4H); MS(ESI,m / z):498.2(M+H) + .
[0287] Example 32 Preparation of 5-[4-(Benzothiophene-4-yl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (32)
[0288]
[0289] 32.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0290] 32.2 According to the method of 30.2 in Example 30, 1-(benzothiophen-4-yl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 43.38%. 1H NMR (400MHz, DMSO-d6) δ7.75(d,J=5.5Hz,1H),7.68(d,J=8.0Hz,1H),7.47(t,J=6.8Hz,2H),7 .39–7.26(m,5H),7.20(s,3H),6.94(d,J=7.6Hz,1H),3.45(q,J=7.0Hz,1H),3.27(s,8H),2.9 7(t,J=7.3Hz,2H),2.80(tt,J=14.6,8.4Hz,2H),2.44(dd,J=16.7,7.8Hz,1H),2.07(dd,J=15 .8,8.6Hz,1H),1.60(dq,J=15.3,7.3Hz,4H),1.07(t,J=7.0Hz,1H); MS(ESI,m / z):496.2(M+H) + .
[0291] Example 33 Preparation of 5-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (33)
[0292]
[0293] 33.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0294] 33.2 According to the method of 30.2 in Example 30, 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 32.71%. 1H NMR (400MHz, DMSO-d6) δ8.10(t,J=9.1Hz,2H),7.59(t,J=7.6Hz,1H),7.46(t,J=7.8Hz,2H),7.35 (d,J=7.4Hz,1H),7.32–7.24(m,3H),7.19(s,3H),3.67(s,4H),3.24(q,J=5.7,5.0Hz,6H),2.95(t ,J=7.3Hz,2H),2.79(ddt,J=20.7,14.2,6.9Hz,2H),2.43(dt,J=14.2,6.6Hz,1H),2.05(dt,J=15. 3,6.6Hz,1H),1.61(dq,J=18.4,8.4,7.7Hz,3H),1.53(d,J=8.2Hz,1H); MS(ESI,m / z):497.2(M+H) + .
[0295] Example 34 Preparation of 5-[4-(2,3-dichlorophenyl)piperazine-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)]pentan-1-one oxalate (34)
[0296]
[0297] 34.1 According to the method of 13.1 in Example 13, 5-chlorovaleryl chloride was used instead of 4-chlorobutyryl chloride to obtain the product with a yield of 76.23%.
[0298] 34.2 According to the method of 13.2 in Example 13, 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was reacted with 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 42.57%. 1 HNMR(400MHz, DMSO-d6)δ7.50(d,J=7.2Hz,1H),7.40(d,J=17.1Hz,2H),7.36–7.30(m,4H),7.25–7.16(m,3H),3.34–3.26(m,1H),3.18(s ,8H),2.92(t,J=7.1Hz,2H),2.87–2.74(m,2H),2.47–2.36(m,1H),2.11–1.97(m,1H),1.57(d,J=12.4Hz,5H); MS(ESI,m / z):542.1(M+H) + .
[0299] Example 35 Preparation of 5-[4-(pyrimidin-2-yl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentane 1-one oxalate (35)
[0300]
[0301] 35.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0302] 35.2 According to the method of 30.2 in Example 30, 2-(piperazin-1-yl)pyrimidine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 30.29%. 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=4.7Hz,2H),7.44(d,J=7.1Hz,1H),7.35(d,J=7.3Hz, 1H),7.32–7.25(m,3H),7.20(s,3H),6.72(t,J=4.8Hz,1H),3.92(s,4H),3.27(td,J=19 .4,18.6,9.8Hz,2H),3.04(t,J=5.1Hz,4H),2.81(dq,J=19.5,12.2,9.4Hz,4H),2.45–2 .36(m,1H),2.04(dd,J=15.5,8.5Hz,1H),1.65–1.48(m,4H);MS(ESI,m / z):442.3(M+H) + .
[0303] Example 36 Preparation of 5-[4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (36)
[0304]
[0305] 36.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0306] 36.2 According to the method of 34.2 in Example 34, 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product in a yield of 46.67%. 1H NMR(400MHz, DMSO-d6)δ8.09(dd,J=8.8,5.3Hz,1H),7.71(dt,J=11.1,5.5Hz,1H),7.51(d ,J=7.2Hz,1H),7.48–7.19(m,7H),3.47(d,J=11.8Hz,2H),3.23(q,J=9.5,7.5Hz,2H),3.08 –2.93(m,4H),2.85–2.72(m,2H),2.48–2.37(m,1H),2.26–2.11(m,4H),2.04(td,J=17.2, 13.7,9.2Hz,1H),1.68–1.61(m,2H),1.55(q,J=8.2,7.7Hz,2H); MS(ESI,m / z):532.2(M+H) + .
[0307] Example 37 Preparation of 5-[3,4-dihydroisoquinolin-2(1H)-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (37)
[0308]
[0309] 37.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0310] 37.2 According to the method of 30.2 in Example 30, 1,2,3,4-tetrahydroisoquinoline was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 32.71%. 1 H NMR(400MHz,DMSO-d6)δ7.45(d,J=7.4Hz,1H),7.36–7.17(m,10H),7.16(d,J=8.0Hz ,1H),4.22(s,2H),3.36–3.18(m,4H),3.01(q,J=6.8,6.3Hz,4H),2.83(d,J=10.8Hz, 1H),2.81–2.73(m,1H),2.43(dt,J=14.8,6.7Hz,1H),2.05(dt,J=15.3,6.9Hz,1H),1 .68(d,J=7.8Hz,1H),1.58(ddd,J=31.1,16.5,7.5Hz,3H); MS(ESI,m / z):411.2(M+H) + .
[0311] Example 38 Preparation of 5-[4-(Benzo[b]thiophen-4-yl)piperazine-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (38)
[0312]
[0313] 38.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0314] 38.2 According to the method of 34.2 in Example 34, 1-(benzothiophen-4-yl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 40.32%. 1 H NMR (400MHz, DMSO-d6) δ7.75(d,J=5.5Hz,1H),7.69(s,1H),7.67(s,1H),7.55–7.47(m,2H),7.46–7.23(m,7H),7.22(s,1H),6.94(d,J=7.7H z,1H),3.25(s,10H),2.95(s,2H),2.84–2.74(m,2H),2.42(d,J=17.0Hz,1H),2.04(d,J=18.3Hz,1H),1.60(s,4H); MS(ESI,m / z):530.2(M+H) + .
[0315] Example 39 Preparation of 5-[4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (39)
[0316]
[0317] 39.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,ff]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0318] 39.2 According to the method of 34.2 in Example 34, 3-(piperazin-1-yl)benzo[d]isothiazole hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 53.77%. 1H NMR(400MHz, DMSO-d6)δ8.10(t,J=8.3Hz,2H),7.59(t,J=7.6Hz,1H),7.54–7. 48(m,1H),7.48–7.26(m,5H),7.26–7.19(m,2H),3.65(s,4H),3.32–3.13(m,6H ),2.92(t,J=7.0Hz,2H),2.87–2.80(m,1H),2.80–2.72(m,1H),2.47–2.37(m,1 H),2.05(td,J=15.9,7.4Hz,1H),1.64–1.50(m,4H); MS(ESI,m / z):531.2(M+H) + .
[0319] Example 40 Preparation of 5-[4-(pyrimidin-2-yl)piperazine-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (40)
[0320]
[0321] 40.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0322] 40.2 According to the method of 34.2 in Example 34, 2-(piperazin-1-yl)pyrimidine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 56.81%. 1 H NMR(400MHz, DMSO-d6)δ8.42(d,J=4.7Hz,2H),7.50(d,J=7.3Hz,1H),7.42–7.19(m,6 H),6.72(t,J=4.9Hz,1H),4.03(q,J=7.1Hz,1H),3.24(td,J=18.5,17.8,10.2Hz,2H) ,3.04(t,J=5.2Hz,4H),2.81(dq,J=24.2,11.2,8.9Hz,5H),2.45–2.35(m,1H),1.99( s,2H),1.55(tt,J=16.4,7.8Hz,4H),1.18(t,J=7.0Hz,1H); MS(ESI,m / z):476.2(M+H) + .
[0323] Example 41 Preparation of 5-[3,4-dihydroisoquinolin-2(1H)-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (41)
[0324]
[0325] 41.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0326] 41.2 According to the method of 34.2 in Example 34, 1,2,3,4-tetrahydroisoquinoline was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 39.15%. 1 H NMR(400MHz, DMSO-d6)δ7.50(d,J=7.4Hz,1H),7.44–7.34(m,3H),7.31(d,J=7.4Hz ,1H),7.23(d,J=8.3Hz,5H),7.16(d,J=6.9Hz,1H),4.21(s,2H),3.37–3.16(m,4H), 3.00(q,J=8.0,7.1Hz,4H),2.86–2.70(m,2H),2.42(t,J=9.0Hz,1H),2.04(td,J=16 .2,7.8Hz,1H),1.70–1.62(m,2H),1.56(q,J=7.7Hz,2H); MS(ESI,m / z):445.2(M+H) + .
[0327] Example 42 Preparation of 5-[4-(2-methoxyphenyl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (42)
[0328]
[0329] 42.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 of Example 30.
[0330] 42.2 According to the method of 30.2 in Example 30, 1-(2-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 48.55%. 1H NMR(400MHz,DMSO-d6)δ7.45(d,J=7.3Hz,1H),7.36(d,J=7.3Hz,1H),7.33–7.26(m ,3H),7.20(s,3H),7.05–6.85(m,4H),3.79(s,3H),3.21(d,J=42.5Hz,10H),2.94( t,J=7.2Hz,2H),2.81(dq,J=18.6,12.0,10.4Hz,2H),2.46–2.38(m,1H),2.05(dd, J=15.4,8.4Hz,1H),1.56(ddq,J=22.7,15.0,7.3Hz,4H); MS(ESI,m / z):470.3(M+H) + .
[0331] Example 43 Preparation of 5-[4-(2-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (43)
[0332]
[0333] 43.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Preparation 34.1 of Example 34.
[0334] 43.2 According to the method of 34.2 in Example 34, 1-(2-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 46.34%. 1 H NMR(400MHz, DMSO-d6)δ7.51(d,J=7.2Hz,1H),7.44–7.35(m,2H),7.34–7.20(m, 4H),6.99(dt,J=13.0,5.1Hz,2H),6.90(d,J=6.0Hz,2H),3.79(s,3H),3.21(d,J= 27.4Hz,10H),2.94(t,J=7.2Hz,2H),2.79(q,J=14.8,12.3Hz,2H),2.47–2.36(m ,1H),2.03(dd,J=16.3,8.9Hz,1H),1.65–1.48(m,4H); MS(ESI,m / z):504.2(M+H) + .
[0335] Example 44 Preparation of 5-[4-(3-methoxyphenyl)piperazine-1-yl]-1-[10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (44)
[0336]
[0337] 44.1 The preparation of 5-chloro-1-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out according to the preparation method of 30.1 in Example 30.
[0338] 44.2 According to the method of 30.2 in Example 30, 1-(3-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 40.12%. 1 H NMR(400MHz, DMSO-d6)δ7.45(d,J=7.2Hz,1H),7.36(d,J=7.4Hz,1H),7.33–7.26(m,3H),7.22 –7.10(m,4H),6.56(d,J=8.3Hz,1H),6.50(s,1H),6.43(d,J=8.3Hz,1H),3.73(s,3H),3.35–3. 23(m,5H),3.10(t,J=5.0Hz,4H),2.89(t,J=7.1Hz,3H),2.83–2.73(m,2H),2.42(dt,J=13.5,5 .9Hz, 1H), 2.05 (dd, J=15.6, 8.3Hz, 1H), 1.55 (q, J=9.9, 7.6Hz, 4H); MS (ESI, m / z): 470.3 (M+H) + .
[0339] Example 45 Preparation of 5-[4-(3-methoxyphenyl)piperazin-1-yl]-1-[3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl]pentan-1-one oxalate (45)
[0340]
[0341] 45.1 The preparation of 5-chloro-1-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)pentan-1-one was carried out as described in Example 34.1.
[0342] 45.2 According to the method of 34.2 in Example 34, 1-(2-methoxyphenyl)piperazine hydrochloride was used instead of 1-(2,3-dichlorophenyl)piperazine hydrochloride to obtain the product with a yield of 42.14%. 1H NMR(400MHz, DMSO-d6)δ7.50(d,J=7.3Hz,1H),7.44–7.19(m,6H),7.14(t,J=8.1Hz,1H),6.56(d d,J=8.3,2.3Hz,1H),6.50(d,J=2.4Hz,1H),6.43(dd,J=8.1,2.2Hz,1H),3.72(s,3H),3.29(d,J= 38.8Hz,6H),3.10(t,J=5.4Hz,4H),2.89(t,J=7.1Hz,2H),2.85–2.80(m,1H),2.80–2.72(m,1H), 2.41(dd,J=16.1,7.7Hz,1H),2.08–1.98(m,1H),1.63–1.48(m,4H); MS(ESI,m / z):504.2(M+H)+.
[0344] Example 46 Preparation of 5-[4-[3,4-dihydroisoquinolin-2(1H)-yl]butyl]-10,11-dihydro-5H-dibenzo[b,f]azepine oxalate (46)
[0345]
[0346] 46.1 Add iminodibenzyl (10 g, 0.051 mol), potassium carbonate (14.15 g, 0.10 mol), potassium iodide (1.69 g, 0.01 mol), 1,4-dichlorobutane (9.72 g, 0.077 mol) and N,N-dimethylformamide (100 mL) into a 100 mL single-necked flask in sequence, stir magnetically, raise the temperature to 90 °C, and react for 10 hours. After the reaction, the reaction solution was filtered, and the filtrate was directly poured into a 500 mL separatory funnel, and 200 mL of water and 200 mL of ethyl acetate were added for extraction. The aqueous phase was extracted twice with ethyl acetate (2×100 mL), and the organic phases were combined, washed twice with saturated sodium chloride solution (2×150 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was separated by silica gel column chromatography (DCM / MeOH=100:1) to obtain a light yellow oily liquid, which was then salified with ethyl acetate solution of oxalic acid to obtain the product with a yield of 31.75%.
[0347] 46.2 According to the method of 1.2 in Example 1, 5-(4-chlorobutyl)-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 1,2,3,4-tetrahydroisoquinoline to obtain the product in a yield of 31.50%. 1H NMR(400MHz, DMSO-d6)δ7.23(dd,J=6.2,3.8Hz,2H),7.19(d,J=7.6Hz,1H),7.13( d,J=4.5Hz,6H),7.11(s,1H),6.93(dq,J=8.3,4.3,3.3Hz,2H),4.24(s,2H),3.74 (t,J=6.6Hz,2H),3.34(q,J=8.5,6.1Hz,2H),3.10(s,4H),3.02(q,J=7.4,6.0Hz, 4H), 1.76 (q, J=7.9, 7.4Hz, 2H), 1.53 (p, J=6.9Hz, 2H); MS (ESI, m / z): 383.2 (M+H) + .
[0348] Example 47 Preparation of 3-chloro-5-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-10,11-dihydro-5H-dibenzo[b,f]azepine oxalate (47)
[0349]
[0350] 47.1 According to the method of 46.1 in Example 46, 3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 1,3-dichloropropane to obtain the product with a yield of 28.34%.
[0351] 47.2 According to the method of 46.2 in Example 46, 3-chloro-5-(3-chloropropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 1-(2-methoxyphenyl)piperazine hydrochloride to obtain the product in a yield of 33.42%. 1 H NMR (400MHz, DMSO-d6) δ7.70 (s, 1H), 7.51 (d, J = 7.3Hz, 1H), 7.47–7.43 (m, 1H), 7.37 (d, J = 6. 4Hz,1H),7.32(s,1H),7.27–7.19(m,3H),6.98(d,J=4.9Hz,1H),6.89(d,J=4.3Hz,2H),3.91– 3.82(m,2H),3.75(s,3H),3.29(d,J=33.6Hz,4H),2.96(t,J=7.7Hz,4H),2.79(dq,J=20.1,1 3.3,10.0Hz,4H),2.13–1.96(m,2H),1.91(dd,J=14.3,7.3Hz,2H); MS(ESI,m / z):462.2(M+H) + .
[0352] Example 48 Preparation of 5-[5-[4-(Benzothiophen-4-yl)piperazin-1-yl]pentyl]-3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepine oxalate (48)
[0353]
[0354] 48.1 According to the method of 46.1 in Example 46, using 1,5-dichloropentane instead of 1,4-dichlorobutane, the product was obtained with a yield of 30.81%.
[0355] 48.2 According to the method of 46.2 in Example 46, 3-chloro-5-(5-chloropentyl)-10,11-dihydro-5H-dibenzo[b,f]azepine was reacted with 1-(benzothiophen-4-yl)piperazine hydrochloride to obtain the product in a yield of 31.88%. 1 H NMR (400MHz, DMSO-d6) δ7.72(d,J=5.4Hz,1H),7.68(d,J=8.0Hz,1H),7.47(d,J=5.5Hz,1 H),7.29(t,J=7.8Hz,1H),7.10(d,J=10.0Hz,5H),6.91(q,J=7.6,5.9Hz,3H),4.01(q,J= 7.1Hz,1H),3.69(t,J=6.7Hz,2H),3.43(s,6H),3.08(s,6H),1.97(s,1H),1.63(s,1H),1 .52(p,J=6.8Hz,2H),1.33(p,J=7.3Hz,2H),1.25–1.12(m,1H); MS(ESI,m / z):516.2(M+H) + .
[0356] Test Example
[0357] Comparative Example Clomipramine and vilazodone are both commercially available and purchased from Shanghai MacLean Biochemical Technology Co., Ltd. The chemical structures of clomipramine and vilazodone are shown below:
[0358]
[0359] Example 49 The inhibitory effect of the compound on brain synaptosome 5-HT and NA and on 5-HT 1A Receptor action
[0360] The present invention uses clomipramine and vilazodone as positive controls to investigate the effects of the invented compounds on inhibiting the reuptake of 5-HT and NA by brain synaptosomes and the effects of 5-HT 1A Study the role of receptors.
[0361] Here’s how:
[0362] Preparation of SERT and NET (tissue) receptor membranes
[0363] The rat cerebral cortex was taken and homogenized with homogenate A (50 mM Tris-HCl, 120 mM NaCl, 5 mM KCl, pH = 7.4), centrifuged at 50000 g, 4 ° C for 10 min, the supernatant was discarded, the homogenate was added and incubated at 37 ° C for 10 min, the precipitate was taken after centrifugation, and 50 mM Tris-HCl buffer (Ph = 7.4) was added for washing, and the centrifugation was repeated three times. After the centrifugation was completed, the supernatant was discarded and the precipitate was stored at -80 ° C for later use.
[0364] 5-HT 1A Preparation of receptor membrane
[0365] Adult SD rats were decapitated on ice, the cerebral cortex was quickly removed, homogenate was added, homogenized with Ultra Turrax tissue homogenizer, and incubated in a 37°C water bath for 10 minutes. High-speed refrigerated centrifuge (48000r, 4°C) was adjusted to centrifuge for 20 minutes. After centrifugation, the supernatant was discarded, the homogenate was added and mixed with a vortex mixer, and centrifuged under the same conditions for three times. After centrifugation, the supernatant was discarded and the precipitate was stored at -80°C for later use.
[0366] 1. SERT receptor competition binding assay
[0367] First, the prepared membrane was dispersed evenly with an appropriate amount of homogenate A (50mM Tris-HCl, NaCl 120mM, KCl 5mM, Ph=7.4) using a homogenizer and set aside; 100μl of the membrane preparation was added to each reaction tube; 100μl of homogenate A was added to the total binding tube (TB), and 100μl of paroxetine (final concentration 1.0*10 -5 M, add 100 μl of test compound (final concentration 1.0*10 -5 M); radioactive ligands were added to each reaction tube [ 3 H]-paroxetine final concentration was 0.5 nM;
[0368] Each reaction tube was incubated at 23°C for 60 min. After the reaction was completed, the bound ligand was quickly filtered under reduced pressure. The Whatman test paper GF / C was saturated with 0.5% PEI solution 1 h in advance and washed thoroughly with ice-cold test buffer. The filter was taken out and placed in a 2 ml scintillation cup, and 1 ml of toluene scintillation fluid was added and mixed; the scintillation bottle was placed in a liquid scintillation counter for counting.
[0369] 2. NET receptor competition binding assay
[0370] First, the prepared membrane was dispersed evenly with an appropriate amount of homogenate A (50 mM Tris-HCl, PH = 7.4) using a homogenizer and set aside; 100 μl of the membrane preparation was added to each reaction tube; 100 μl of homogenate A was added to the total binding tube (TB), and 100 μl of desipramine (final concentration 1.0*10 -5 M, add 100 μl of test compound (final concentration 1.0*10 -5 M); radioactive ligands were added to each reaction tube [ 3 The final concentration of H]-Nisoxetine was 0.5 nM; each reaction tube was incubated at 25°C for 30 min. After the reaction was completed, the bound ligand was quickly filtered by vacuum filtration. The Whatman test paper GF / C was saturated with 0.5% PEI solution 1 h in advance and washed thoroughly with ice-cold test buffer. The filter was taken out and placed in a 2 ml scintillation cup, and 1 ml of toluene scintillation fluid was added and mixed; the scintillation bottle was placed in a liquid scintillation counter for counting.
[0371] 3. 5-HT 1A Receptor competition binding assay
[0372] Take appropriate amount of 5-HT 1A Add 50 mL of homogenate to the membrane and disperse it into a suspension using a homogenizer; place the reaction tubes on ice and add 900 μL of the suspension to each tube; add 50 μL of 0.05 M Tris-HCl buffer to the total binding tube (TB), 50 μL of 10 μM 5-HT to the nonspecific binding tube (NB), and 50 μL of the test compound to the specific binding tube (SB); add 0.5 nM of radioligand to all reaction tubes. 3 H-8-OH-DPAT (187.4Ci / mmol) 50μL. Incubate each reaction tube at 37°C for 30 minutes, and place on ice to cool after incubation to quench the reaction. Use GF / C glass fiber filter paper (purchased from Whatman) to quickly filter under reduced pressure, wash the filter with ice-cold test buffer, take out the filter after washing and put it in a scintillation cup, add 3mL of toluene scintillation liquid and mix well, and put the scintillation bottle into a liquid scintillation counter for counting.
[0373] Example 50 Compounds of the present invention interact with SERT, NET and 5-HT 1A Receptor binding ability
[0374] The experimental results are shown in Table 1:
[0375]
[0376]
[0377]
[0378] As can be seen from the table, the compounds of the present invention have good inhibitory activity against SERT and NET, and have a good inhibitory effect on 5-HT. 1A In particular, preferred compounds 20, 27, 31 and 40 have strong SERT and NET inhibitory activity in vitro (stronger than the positive control drug clomipramine) and have strong inhibitory effects on 5-HT 1A The receptors have a stronger effect (stronger than the positive control drug vilazodone).
[0379] Example 51 Study on the antidepressant activity of the compounds of the present invention in animals
[0380] The "tail suspension test" and "forced swimming test" in the acquired despair experiment were used to conduct a preliminary study on the antidepressant effect of the compound of the present invention in vivo, using clomipramine and vilazodone as positive control drugs.
[0381] The day before the experiment, mice with qualified weight were screened and randomly divided into groups of 8 mice each, and a vehicle control group and a positive control group were set up. Each group was given the drug by gavage (ig), and the drug was given 1 hour before each experiment.
[0382] In the tail suspension test, mice were taped 1 cm from the tip of their tails and then suspended for 6 minutes, and video was recorded. Software or manual analysis was then used to analyze the immobility time of the mice for 4 minutes after the 6-minute tail suspension period.
[0383] In the forced swimming test, mice were placed in a transparent glass cylinder (water depth 15 cm, water temperature 23-25°C) for 6 min and video recorded for 6 min. The immobility time of the mice in the last 4 min of the 6 min swimming period was then analyzed by software or manually.
[0384] Table 2 Effects of compounds 20, 27, 31 and 40 on the tail suspension immobility time of mice
[0385]
[0386] *P<0.05, **P<0.01 compared with the blank control group.
[0387] Table 3 Effects of compounds 20, 27, 31 and 40 on the immobility time of forced swimming in mice
[0388]
[0389] *P<0.05, **P<0.01 compared with the blank control group.
[0390] As shown in Tables 2 and 3, in the mouse tail suspension test and forced swimming test, the compound of the present invention can significantly shorten the time of immobility due to despair. The shorter the immobility time, the stronger the antidepressant effect. At the same dose, the antidepressant effect of the compound of the present invention is significantly stronger than that of clomipramine and vilazodone.
[0391] Example 52 Acute toxicity of the compound of the present invention in mice after single oral administration
[0392] The Bliss method was used to test the acute toxicity median lethal dose (LD50) of a single oral administration to mice. 50 ).
[0393] (1) Limiting experiment of sequential method
[0394] Experimental method: ICR mice, half male and half female, were randomly divided into several groups, each with 5 mice, and each group was given 2000 mg / kg of each compound and solvent, respectively, and 0.2 ml / 10 g was administered by gavage. The death of the animals within 3 days was observed (if 3 or more animals survived within 3 days and there was no obvious abnormality in their life status, the observation was continued until the end of the experiment after 7 days. If 3 or more animals died within 3 days, the LD50 method was used to determine the LD50 50 ).
[0395] (2) Median lethal dose experiment
[0396] Experimental method: ICR mice, half male and half female, were randomly divided into several groups, 5 mice in each group, which were 1000 mg / kg, 500 mg / kg, 200 mg / kg, 100 mg / kg group of each compound and solvent group. The mice were intragastrically administered at 0.2 ml / 10 g and the death of the animals was observed within 1-3 days.
[0397] Table 4 Acute toxicity of the compounds of the present invention to mice 50 )
[0398] The acute toxicity of compounds 20, 27, 31 and 40 to mice after oral administration was LD50. 50 )
[0399] Compound <![CDATA[LD 50 (mg / kg)]]> 20 1228 27 859 31 1054 40 916 Clomipramine 470
[0400] As can be seen from the table, the acute toxicity of the representative compounds of the present invention is better than that of clomipramine.
Claims
1. A compound represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, in: R1 and R2 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; R3 is oxygen or sulfur; R4 is hydrogen, deuterium, halogen, hydroxy, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; Q is CR5R6 or NR7; R5 and R6 are each independently hydrogen, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio; or R5 or R6 and R4 and the carbon atom to which they are attached together form C 6-14 Aryl; or R5 is In this case, R6 is hydrogen, wherein Ar is a 5-8 membered heterocyclic group, R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a group optionally replaced by one or more R 10 Substituted C 6-14 aryl; R7 is Wherein Ar is a 5-8 membered heterocyclic group, C 6-14 aryl, 5-14 membered heteroaryl, R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a radical optionally substituted by one or more R 10 Substituted C 6-14 Aryl, or R8 and R9 and the carbon atom to which they are attached together form an aryl group optionally substituted by one or more R 10 substituted 5-8 membered heterocyclic group; R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; x is an integer from 0 to 4; y is an integer from 0 to 4; m is an integer from 2 to 8.
2. The compound of general formula (I) according to claim 1 or its pharmaceutically acceptable salt, stereoisomer, or tautomer, characterized in that: It meets one or more of the following conditions: (1) R1 and R2 are each independently hydrogen, deuterium, halogen, or hydroxyl; (2) R3 is oxygen or sulfur; (3) R4 is hydrogen, deuterium, hydroxyl, C1-C6 alkyl, C1-C6 deuterated alkyl, or C1-C6 haloalkyl; (4) Q is CR5R6 or NR7; R5 and R6 are each independently hydrogen, cyano, amino, oxo, C1-C6 alkyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; or R5 or R6 and R4 together with the carbon atom to which they are attached form C 6-14 Aryl; or R5 is In this case, R6 is hydrogen, wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, and R8 and R9 together with the carbon atom to which they are attached form a group optionally replaced by one or more R 10 Substituted C 6-14 aryl; R7 is wherein Ar is a 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S, C 6-14 aryl, a 5-14 membered heteroaryl containing 1-4 heteroatoms selected from N, O or S, R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form ... 10 Substituted C 6-14 Aryl, or R8 and R9 and the carbon atom to which they are attached together form an aryl group optionally substituted by one or more R 10 substituted 5-8 membered heterocyclic group containing 1-4 heteroatoms selected from N, O or S; R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; x is an integer from 0 to 4; y is an integer from 0 to 4; m is an integer from 2 to 4.
3. The compound of general formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, characterized in that: The general formula (I) is further represented by the general formula (II), the general formula (III) or the general formula (IV): Wherein, R1 is hydrogen, deuterium, halogen, or hydroxyl; R3 is oxygen or sulfur; R8 and R9 are each independently hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio, or R8 and R9 and the carbon atom to which they are attached together form a 5-8 membered heterocyclic group containing a sulfur heteroatom; m is an integer from 2 to 4.
4. The compound of general formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, characterized in that: The general formula (I) is further represented by the general formula (V) or the general formula (VI): Wherein, R1 is hydrogen, deuterium, halogen, or hydroxyl; R3 is oxygen or sulfur; R 10 is hydrogen, deuterium, halogen, hydroxyl, mercapto, cyano, amino, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 deuterated alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C1-C6 alkylthio; m is an integer from 2 to 4.
5. The compound of general formula (I) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof according to any one of claims 1 to 4, characterized in that: Selected from the following compounds:
6. The compound of general formula (I) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof according to any one of claims 1 to 5, characterized in that: The pharmaceutically acceptable salt is selected from hydrochloride, hydrobromide, sulfate, phosphate, succinate, malonate, acetate, oxalate, benzoate, citrate, tartrate, nicotinate, lactate, furoate, maleate, fumarate, methanesulfonate, ethanesulfonate, benzenesulfonate or p-toluenesulfonate.
7. A method for preparing the compound represented by general formula (I) according to claim 1 or its pharmaceutically acceptable salt, stereoisomer, or tautomer, characterized in that: include: Step 1: Step 2: wherein R1, R3, and R4 are as defined in any one of the preceding claims; Q is CR5R6 or NR7; R5 and R6 are as defined in any one of the preceding claims; Or R5 is In this case, R6 is hydrogen, wherein Ar, R8, and R9 are as defined in any one of the preceding claims; R7 is Among them, Ar, R8, R 9、 R 10 As defined in any one of the preceding claims; R 11 is a halogen; R 12 is halogen, hydroxyl; m is an integer of 2-8, preferably m is an integer of 2-4.
8. A pharmaceutical composition comprising a therapeutically effective dose of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, and one or more pharmaceutically acceptable carriers or excipients.
9. The compound according to any one of claims 1 to 6 or its pharmaceutically acceptable salt, stereoisomer, tautomer, or the pharmaceutical composition according to claim 8 in the preparation of a 5-hydroxytryptamine 5-HT and norepinephrine NA reuptake inhibitor and / or a 5-HT 1A Receptor agonist or antagonist drugs.
10. Use of the compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, or the pharmaceutical composition according to claim 8, in the preparation of a medicament for preventing and / or treating a neuropsychiatric disease, wherein the neuropsychiatric disease is selected from one or more of schizophrenia, depression, pain, sleep disorders, or Alzheimer's disease, preferably depression.
